Moolec Science (MLECW) Land & Improvements (2024 - 2025)
Moolec Science (MLECW) posted Land & Improvements of $100896.0 for Q2 2025, down 99.32% sequentially from $14.9 million in Q2 2024, and down 99.32% YoY from $14.9 million in Q2 2024.
Moolec Science (MLECW) Land & Improvements (2024 - 2025) Analysis & Trends
Moolec Science has reported Land & Improvements for 2 years, with the latest figure at $100896.0 in Q2 2025.
- Quarterly Land & Improvements fell 99.32% year-over-year to $100896.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $100896.0 (down 99.32% YoY) and the FY2025 annual result came in at $100896.0, down 99.32% from the prior year.
- Land & Improvements slipped to $100896.0 in Q2 2025 per MLECW's latest filing, from $14.9 million in the prior quarter.
- Over five years, Land & Improvements peaked at $14.9 million in Q2 2024 and troughed at $100896.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 100,896.00 |
| Jun 30, 2024 | 14.92 Mn |